Latest Tarceva Stories
One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time.
The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.
Panel Votes Against Approval of Tarceva(R) as Maintenance Drug WASHINGTON, Dec. 17 /PRNewswire-USNewswire/ -- Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.
NEW YORK, Sept.
The mixture of two anti-cancer medications, along with chemotherapy, can gradually halt advanced non-small cell lung cancer, says a new study released on Saturday.
WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y., May 28 /PRNewswire-FirstCall/ -- Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc.
Genentech, a biotechnology company, and OSI Pharmaceuticals, have announced that a global Phase III study has met its primary endpoint and showed that Tarceva significantly extended the time patients with advanced non-small cell lung cancer lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo.
Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc.
A GRANDMOTHER with terminal cancer who faced moving to get life- saving drugs on the NHS has won her battle with Midland health bosses to receive her medication. Carol Rummels, from Stoke Lodge, in Bristol, considered moving to Scotland so she could continue to take the drug Tarceva.
By ; wire Shares of South San Francisco-based Genentech dropped nearly 8 percent after the company announced with OSI Pharmaceuticals that a combination of two cancer drugs, Avastin with Tarceva, missed its primary goal in a clinical trial, failing to improve survival for patients with late-stage lung cancer.